BCL2L1 and acute lymphoblastic leukemia: Inhibition of CK2 restores Ikaros-mediated repression of BCL2L1 and enhances sensitivity of B-ALL cells to doxorubicin, demonstrating a beneficial effect of CK2 inhibition in this setting.